CSIMarket Company Name, Ticker, Customers, else..
 

Gamida Cell Ltd   (NASDAQ: GMDA)

Gamida Cell Ltd 's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

GMDA Sales vs. its Competitors Q1 2024


Comparing the current results to its competitors, Gamida Cell Ltd reported Revenue increase in the 1 quarter 2024 by 0 % year on year, while most of its competitors have experienced contraction in revenues by -4.06 %, achieved in the same quarter.

• List of GMDA Competitors

With a net margin of 2241.12 % Gamida Cell Ltd achieved higher profitability than its competitors.

• More on GMDA Profitability Comparisons



Revenue Growth Comparisons




Net Income Comparison

Gamida Cell Ltd achieved net profit of $19.95 millions compared to a net loss of $-20.96 millions recorded in the same quarter a year ago.

<<  GMDA Stock Performance Comparisons





*Market share is calculated based on total revenue.

  News about Gamida Cell Ltd Contracts

Gamida Cell Presents Positive Data on Omidubicel's Efficacy in Hematopoietic Recovery and Infection Rates

February 23, 2024
 In recent data presented at the 2024 Tandem Meetings of ASTCT and CIBMTR, Gamida Cell showcased the results of their Expanded Access Program (EAP) for omidubicel. The presented data supported the positive outcomes observed in the Phase 3 trial, with regards to rates of hematopoietic recovery and infections following stem cell transplant with Omisirge (omidubicel-onlv). This article aims to delve into the key insights from the data and their implications for advancing stem cell transplantation therapies.The Omidubicel Study:The EAP data presented by Gamida Cell focused on evaluating the efficacy of omidubicel in achieving successful hematopoietic recovery and reducing infections. Hematopoietic recovery refers...





Publicly Traded Peers of Gamida Cell Ltd




Avalon Globocare Corp
Share Performance



-90.38%
One Year
Avalon Globocare Corp
Profile

Avalon Globocare Corp's business model is focused on providing innovative healthcare solutions and services through strategic acquisitions, partnerships, and collaborations in the biotechnology and healthcare sectors.

More about Avalon Globocare Corp's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.172 mill. $ - mill. $ -8.979 mill.


Genenta Science S p a
Share Performance



-2.24%
Over The Past 5 Days
Genenta Science S p a
Profile

Genenta Science S.p.A. operates on a business model focused on the development of immuno-gene therapies for the treatment of cancer. They aim to leverage their proprietary technology to genetically modify autologous hematopoietic stem cells and engineer them to express immunomodulatory protein IL-12. These modified cells are then reinfused into patients to stimulate an immune response against tumors, potentially offering a novel and personalized approach to cancer treatment.

More about Genenta Science S p a 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ - mill. $ - mill. $ -7.313 mill.


Immunitybio inc
Share Performance



-1.12%
Over The Past 5 Days
Immunitybio inc
Profile

Immunitybio Inc operates on a business model that focuses on developing and commercializing innovative immunotherapies and vaccines to address various diseases and medical conditions. They aim to use their broad scientific expertise, technology platforms, and strategic partnerships to advance their products and improve patient outcomes in healthcare.

More about Immunitybio inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8,773.335 mill. $ 165.792 mill. $ -992.419 mill.


Immunocore Holdings Plc
Share Performance



-4.00%
Over The Past 5 Days
Immunocore Holdings Plc
Profile

The company develops bispecific T cell receptor therapeutics targeting cancer, infectious diseases, and autoimmune disorders.

More about Immunocore Holdings Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,565.916 mill. $ 430.775 mill. $ -18.074 mill.


Iovance Biotherapeutics inc
Share Performance



+389.91%
One Year
Iovance Biotherapeutics inc
Profile

Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.

More about Iovance Biotherapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 4,918.315 mill. $ 324.969 mill. $ -289.517 mill.

26 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Gamida Cell Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gamida Cell Ltd versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.